

Medical cannabis in Europe is not covered by a harmonised regulatory framework. However, Arriello director of drug safety, Peter Kohut, argues that this should not deter pharma companies from pursuing this increasingly attractive opportunity.
Read more...Gabriela Marton, Regulatory Affairs Director and Quality Director at Arriello, highlights EU regulatory challenges and calls for policy changes and education to maximize the opportunity for biosimilars to enhance patient outcomes.
Read more...There is considerable variation in the regulatory approach to medical cannabis between European countries. Yet, despite the complexity, there are clear routes to market, reports Peter Kohut.
Read more...Why are Safety & Pharmacovigilance departments lagging in their application of smart technology, when the pressures on pharmaceutical organisations to capture, sift and process real-world adverse event data are vast, asks John Price, a life sciences regulatory and safety consultant and advisor to Arriello.
Read more...